Industry News + Announcements
We thank our industry partners and advertisers for supporting JIPO, and we encourage our readers to explore the latest headlines from these organizations below.
Top 10 Articles Published in JIPO: April-September 2020
In JIPO, the #1 most read and most downloaded article in 2020 is “Extracellular Signal-Regulated Kinase (ERK) Inhibitors in Oncology Clinical Trials” by Haelee M. Chin, David K. Lai, and Gerald S. Falchook. This article has been viewed more than 1000 times and downloaded more than 175 times.
Another popular JIPO article, with more than 700 views and 150 downloads, is “Are cancer patients at higher risk of death with COVID-19” by Jacob J. Adashek, Joud Hajjar, Roy F. Chemaly, and Razelle Kurzrock.
Also, be sure to read classic editorial by Dr. Aung Naing, Editor in Chief of JIPO, entitled “Being realistic and optimistic in curing cancer.” This article has been viewed and downloaded more than 1000 times in 2020 alone.
Download the full top 10 list here.
The TIGIT Therapies Digital Summit 26-27 October 2020 ONLINE
October 1, 2020 - The TIGIT checkpoint has gained much attention in recent years due to the number of roles it plays in several malignancies. TIGIT's diverse function in multiple cell types has made it a lucrative immunotherapy candidate, with an increasing number of candidates being investigated in pre-clinical and clinical settings. As evidence of TIGIT's clinical potential builds, the TIGIT Therapies Digital Summit (October 26-27) brings you a comprehensive insight, from the fundamental biology to early clinical development, and the next wave of ICI. Read more.
Speaker Interview: TIGIT and the New Wave of Immune Checkpoint Inhibitors
October 1, 2020 - Dr. Dhan Chand (Scientific Director Head of Drug Discovery, Agenus Inc.) discusses the challenges and promise in developing the next clinically validated checkpoints. Download here.
Harnessing the Potential of Macrophage Therapies Using Small Molecule, Antibody, and Cell Therapy-Based Approaches for Oncology and Beyond
September 17, 2020 - With the explosive excitement and clinical proof of concepts utilizing CD47 approaches, macrophage-directed therapies have started to witness interest and investment in novel macrophage targets outside of CD47. The digital 2nd Macrophage-directed Therapies Summit (October 27-29) is focused on optimizing the potential of macrophage therapies, through direct utilization of cells or small molecule approaches to target and stimulate macrophage cells in vivo for oncological indications and beyond. Read more.
Interested in advertising? Please visit https://innovativehci.com/advertising.
